Ginkgo partners with Modulus to add to its cell therapy tool box
2024-04-02
细胞疗法并购免疫疗法
Ginkgo Bioworks has been on a cell-and-gene tool collecting spree this year, and its latest acquisition is Modulus Therapeutics’ library of switch receptors and CARs.
The suite of cell therapy components includes NK- and T-cell specific CAR and switch receptors, which are intended to improve the safety and efficacy of cell therapies by allowing for more precise control over activation and targeting.
The custom CARs are designed to enhance a cell therapy’s proliferation and cytotoxicity to generate a more robust and durable response against target cells.
The switch receptors use specific ligands to enable CAR-T or CAR-NK cell therapies to respond to environmental signals, including inhibitory ones.
One such partner is Wisconsin Alumni Research Foundation, who linked up with Ginkgo last year to discover next-generation GD2 CAR-T cell therapies with improved persistence, proliferation, fitness to treat solid tumours.
Tuesday’s deal with Modulus follows a series of collaborations to bulk out the synthetic biology company’s genetic medicines offerings. Earlier this year, Ginkgo gained several key technologies, including ProteoNic’s vector production platform; Form Bio’s in silico suite for construct characterisation, simulation, and design optimization; and Patch Biosciences’s AI toolkit for DNA sequence design for more effective, specific, and durable genetic medicines.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。